Cardiac Sarcoidosis with Cardiogenic Shock or Rapidly Progressive Disease — When Initial Corticosteroid Therapy Has Not Achieved Disease Control

Clinical scenario

This protocol addresses cardiac sarcoidosis presenting with life-threatening cardiac manifestations — including cardiogenic shock — or rapidly progressive disease, where the initial high-dose corticosteroid strategy has not brought inflammation under control.

Why escalation is needed — prior treatment failure

The preceding treatment step used high-dose intravenous methylprednisolone followed by oral prednisone. Escalation to this protocol is triggered when reassessment at 2 to 6 months shows that cardiac FDG-PET has not demonstrated decreased or resolved myocardial inflammation, or when arrhythmias, heart block, or heart failure have not improved or resolved.

Next treatment step (partial overview)

This protocol calls for adding a previously unused steroid-sparing immunosuppressant in combination with adjusted corticosteroid dosing. Agent selection, initiation approach, and the full titration sequence are detailed in the complete structured regimen.

Treatment goal

Reassessment at 2 to 6 months with cardiac FDG-PET showing minimal residual or resolved myocardial inflammation.

Instant Access to Structured Evidence-Based Regimens

References

For those with life-threatening manifestations such as cardiogenic shock, higher initial corticosteroid doses, including intravenous doses of methylprednisolone of up to 1000 mg/d, can be prescribed until other causes of acute myocarditis (such as giant-cell myocarditis) are excluded.

In a tiered approach to treatment (Figure 3), individuals with relapse or ongoing inflammation after corticosteroids would receive a second-line agent (methotrexate, mycophenolate, azathioprine, or leflunomide) in combination with corticosteroids.

DOI: 10.1161/CIR.0000000000001240

View source ↗